Standard Chemical & Pharmaceutical Co., Ltd. (TPE:1720)
Taiwan · Delayed Price · Currency is TWD 63.10
+0.10 (0.16%)
Jun 5, 2026, 1:30 PM CST
TPE:1720 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,035 | 7,023 | 6,789 | 6,240 | 5,851 | 4,604 | |
Revenue Growth (YoY) | 3.21% | 3.44% | 8.81% | 6.64% | 27.09% | 6.94% |
Cost of Revenue | 4,106 | 4,114 | 3,801 | 3,514 | 3,364 | 2,536 |
Gross Profit | 2,929 | 2,909 | 2,989 | 2,725 | 2,488 | 2,068 |
Selling, General & Admin | 1,281 | 1,288 | 1,293 | 1,209 | 1,100 | 948.47 |
Research & Development | 259.33 | 260.36 | 288.09 | 266.27 | 251.88 | 241.79 |
Operating Expenses | 1,540 | 1,546 | 1,592 | 1,466 | 1,369 | 1,191 |
Operating Income | 1,389 | 1,363 | 1,397 | 1,260 | 1,118 | 876.83 |
Interest Expense | -9.25 | -8.45 | -15.07 | -25.42 | -18.78 | -7.25 |
Interest & Investment Income | 125.38 | 122.52 | 50.48 | 76.84 | 39.45 | 24.99 |
Earnings From Equity Investments | -4.98 | -4.66 | -11.36 | 41.56 | 61.37 | -6.16 |
Currency Exchange Gain (Loss) | -15.57 | -15.57 | 86.85 | 5.62 | 170.44 | -25.6 |
Other Non Operating Income (Expenses) | 47.92 | 42.97 | 51.08 | 30.1 | 35.44 | 77.66 |
EBT Excluding Unusual Items | 1,533 | 1,500 | 1,558 | 1,388 | 1,406 | 940.47 |
Gain (Loss) on Sale of Investments | 8.25 | 15.73 | -0.67 | 5.53 | 1.36 | 1.46 |
Gain (Loss) on Sale of Assets | -1.09 | -1.09 | -5.47 | 1.27 | -7.78 | 73.78 |
Asset Writedown | -0.4 | -0.4 | - | - | - | -1.81 |
Other Unusual Items | 0.01 | 0.01 | -0.19 | 0.02 | 0.11 | -66.45 |
Pretax Income | 1,540 | 1,514 | 1,627 | 1,438 | 1,400 | 1,014 |
Income Tax Expense | 265.46 | 258.35 | 333.05 | 279.94 | 246.31 | 176.95 |
Earnings From Continuing Operations | 1,274 | 1,256 | 1,294 | 1,158 | 1,154 | 836.8 |
Minority Interest in Earnings | -309.8 | -327.87 | -413.81 | -323.04 | -338.21 | -130.07 |
Net Income | 964.51 | 927.66 | 880.5 | 834.89 | 815.41 | 706.73 |
Net Income to Common | 964.51 | 927.66 | 880.5 | 834.89 | 815.41 | 706.73 |
Net Income Growth | 17.27% | 5.36% | 5.46% | 2.39% | 15.38% | 34.83% |
Shares Outstanding (Basic) | 179 | 179 | 179 | 179 | 179 | 179 |
Shares Outstanding (Diluted) | 179 | 179 | 179 | 179 | 179 | 179 |
Shares Change (YoY) | 0.17% | 0.01% | 0.01% | 0.00% | -0.02% | 0.02% |
EPS (Basic) | 5.40 | 5.19 | 4.93 | 4.67 | 4.56 | 3.95 |
EPS (Diluted) | 5.38 | 5.18 | 4.92 | 4.67 | 4.56 | 3.95 |
EPS Growth | 16.94% | 5.29% | 5.35% | 2.41% | 15.44% | 34.81% |
Free Cash Flow | 1,413 | 1,274 | 1,098 | 710.83 | 31.78 | 613.56 |
Free Cash Flow Per Share | 7.88 | 7.12 | 6.14 | 3.97 | 0.18 | 3.43 |
Dividend Per Share | 2.000 | 2.000 | 2.800 | 2.700 | 2.500 | 2.500 |
Dividend Growth | -28.57% | -28.57% | 3.70% | 8.00% | - | 38.89% |
Gross Margin | 41.64% | 41.42% | 44.02% | 43.68% | 42.51% | 44.91% |
Operating Margin | 19.75% | 19.41% | 20.57% | 20.19% | 19.11% | 19.05% |
Profit Margin | 13.71% | 13.21% | 12.97% | 13.38% | 13.94% | 15.35% |
Free Cash Flow Margin | 20.08% | 18.14% | 16.18% | 11.39% | 0.54% | 13.33% |
EBITDA | 1,797 | 1,765 | 1,772 | 1,579 | 1,389 | 1,073 |
EBITDA Margin | 25.55% | 25.13% | 26.09% | 25.30% | 23.74% | 23.31% |
D&A For EBITDA | 407.78 | 402.18 | 375.06 | 319.44 | 270.67 | 196.31 |
EBIT | 1,389 | 1,363 | 1,397 | 1,260 | 1,118 | 876.83 |
EBIT Margin | 19.75% | 19.41% | 20.57% | 20.19% | 19.11% | 19.05% |
Effective Tax Rate | 17.24% | 17.07% | 20.47% | 19.47% | 17.59% | 17.46% |